Progyny Inc
$ 24.55
-1.60%
03 Dec - close price
- Market Cap 2,116,496,000 USD
- Current Price $ 24.55
- High / Low $ 25.08 / 24.47
- Stock P/E 39.60
- Book Value 6.55
- EPS 0.62
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.11 %
- 52 Week High 27.51
- 52 Week Low 13.86
About
Progyny Inc. (PGNY) is a leading benefits management company specializing in innovative fertility and family-building solutions aimed at enhancing employee wellness for organizations across the United States. Headquartered in New York, the firm leverages advanced technology and a diverse network of fertility providers to deliver personalized support, helping employees navigate their reproductive journeys effectively. With a strong commitment to increasing access to high-quality care, Progyny not only improves health outcomes but also helps reduce healthcare costs for employers, positioning itself as a vital partner in the evolving landscape of employee health benefits. As demand for comprehensive family support continues to rise, Progyny remains at the forefront of transforming workplace benefits.
Analyst Target Price
$29.11
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-08-07 | 2025-05-07 | 2025-02-25 | 2024-11-12 | 2024-08-06 | 2024-05-09 | 2024-02-27 | 2023-11-07 | 2023-08-03 | 2023-05-08 | 2023-02-27 |
| Reported EPS | 0.45 | 0.48 | 0.48 | 0.42 | 0.4 | 0.17 | 0.17 | 0.13 | 0.16 | 0.15 | 0.18 | 0.03 |
| Estimated EPS | 0.1251 | 0.16 | 0.4457 | 0.37 | 0.13 | 0.17 | 0.13 | 0.11 | 0.12 | 0.1 | 0.07 | 0.01 |
| Surprise | 0.3249 | 0.32 | 0.0343 | 0.05 | 0.27 | 0 | 0.04 | 0.02 | 0.04 | 0.05 | 0.11 | 0.02 |
| Surprise Percentage | 259.7122% | 200% | 7.6958% | 13.5135% | 207.6923% | 0% | 30.7692% | 18.1818% | 33.3333% | 50% | 157.1429% | 200% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PGNY
2025-10-17 18:22:33
Progyny (PGNY) shares experienced volatility after the Trump administration announced a new initiative to broaden IVF access, including discounted pricing agreements with EMD Serono, raising concerns about potential revenue impact. Despite these concerns, Progyny maintains robust financial health with strong revenue growth and profitability. The company's valuation metrics suggest fair market positioning, balanced by regulatory risks and competitive pressures.
2025-10-17 17:11:40
Progyny (PGNY) stock experienced volatility following the Trump administration's announcement of an initiative to expand IVF access and a drug pricing deal with EMD Serono of Merck KGaA. Analysts are debating the potential impact on Progyny's prescription revenue and its market position, while largely viewing expanded fertility benefits for smaller employers as a positive.
2025-10-17 04:47:55
Progyny (PGNY) stock experienced its best day in two months after BofA Securities reiterated a 'Buy' rating due to a forthcoming White House initiative to expand access to in-vitro fertilization (IVF). The Trump administration plans to unveil measures including guidance for employers to offer supplemental fertility insurance and steep discounts on key IVF drugs. This policy is seen as an "incremental positive" for Progyny, a market leader well-positioned to benefit from increased awareness and utilization of IVF coverage.
2025-10-17 03:41:18
Progyny shares experienced their best day in two months after BofA Securities reiterated a 'Buy' rating, citing a potential White House initiative to expand IVF access as an "incremental positive." The proposed policy includes guidance for employers to offer supplemental fertility insurance and significant discounts on key IVF drugs. Retail sentiment towards Progyny on Stocktwits turned "extremely bullish" following the news, with traders anticipating further upside.
2025-10-16 19:56:18
Bank of America has reiterated its Buy rating for Progyny (PGNY) with a $30 price target, following news of potential policy changes to expand IVF access. Progyny, a leader in fertility benefits management, is well-positioned to benefit from increased demand and coverage for IVF services. Despite strong financial health and market positioning, insider selling activity introduces a note of caution for investors.
2025-10-16 19:03:38
Progyny (PGNY) shares rose following news that the White House plans to propose policies enhancing IVF accessibility by encouraging employers to offer comprehensive coverage. Progyny, a fertility benefits provider, stands to benefit from this expansion of infertility treatment coverage. The company exhibits strong financial health and positive analyst sentiment, though insider selling and a high P/E ratio are noted.
